Combination of<unk> s with other serotonergic drugs such as ergot alkaloids, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs) or St John's wort has been alleged to induce symptoms of a serotonin syndrome (a syndrome of changes in mental status, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms), whereas scientific studies indicate there is no potential for life-threatening serotonin syndrome in patients taking<unk> s and SSRI or SNRIs at the same time, although the FDA has officially stated otherwise. Combining<unk> s with ergot alkaloids is contraindicated because of the danger of coronary spasms. In a study from Harvard Medical School and the University of Florida College of Medicine involving 47,968 patients and published on 26 February 2018, concomitant use of a selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor for depression with a<unk>  for migraine did not demonstrate an increased risk of the serotonin syndrome. Pharmacokinetic interactions (for example, mediated by CYP liver enzymes or transporter proteins) are different for the individual substances; for most<unk> s, they are mild to absent. Eletriptan blood plasma levels are increased by strong inhibitors of CYP3A4, and frovatriptan levels by CYP1A2 inhibitors such as fluvoxamine.
Triptan
Sumatriptan
Frovatriptan
Rizatriptan
Eletriptan
Almotriptan
Zolmitriptan
Naratriptan